We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Teva said Tuesday that it will end development of Ajovy (fremanezumab) in cluster headaches after a pre-specified futility analysis of a Phase III study in episodic cluster headache revealed that the trial’s primary endpoint is unlikely to be met.